# Tocilizumab for KSHV-Associated Multicentric Castleman Disease

> **NCT01441063** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- Castleman Disease
- Multicentric Castleman Disease
- Giant Lymph Node Hyperplasia

## Interventions

- **DRUG:** Zidovudine
- **DRUG:** Tocilizumab
- **DRUG:** Valganciclovir (VGC)

## Key facts

- **NCT ID:** NCT01441063
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-13
- **Primary completion:** 2018-06-06
- **Final completion:** 2020-10-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441063, "Tocilizumab for KSHV-Associated Multicentric Castleman Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01441063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*